GRIN Therapeutics Secures $50 Million Deal with Angelini Pharma for Radiprodil
Deal News | Jun 11, 2025 | Goodwins
GRIN Therapeutics, a company focused on developing precision therapeutics for pediatric neurodevelopmental disorders, has entered into an exclusive collaboration with Angelini Pharma. Under the agreement, GRIN retains rights to radiprodil in North America while granting Angelini exclusive rights in the rest of the world. The initial payment to GRIN is $50 million, with potential for further earnings of up to $520 million based on developmental and sales milestones. Goodwin provided advisory services for this deal. GRIN's motivation stems from promising clinical trial results for radiprodil in treating GRIN-related neurodevelopmental disorder, with plans to proceed to a global Phase 3 trial.
Sectors
- Pharmaceuticals
- Life Sciences
- Legal Services
Geography
- North America – GRIN Therapeutics retains exclusive rights to radiprodil in the United States, Canada, and Mexico.
- Global – Angelini Pharma gains commercialization rights for radiprodil outside North America, indicating a global reach for this pharmaceutical product.
- Europe – Angelini Pharma is based in Europe, and this region will be a key market for radiprodil outside North America.
Industry
- Pharmaceuticals – The article revolves around GRIN Therapeutics' pharmaceutical collaboration with Angelini Pharma to develop and commercialize radiprodil outside North America.
- Life Sciences – GRIN Therapeutics is involved in life sciences with its focus on developing treatments for pediatric neurodevelopmental disorders.
- Legal Services – Goodwin provided legal advice for the collaboration agreement between GRIN Therapeutics and Angelini Pharma.
Financials
- $50 million – Upfront payment by Angelini Pharma to GRIN Therapeutics as part of the exclusive collaboration agreement.
- $520 million – Potential additional earnings for GRIN Therapeutics through developmental, regulatory, and sales milestones.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| GRIN Therapeutics, Inc. | Target Company | Company | A company focused on research and development of precision therapeutics for pediatric neurodevelopmental disorders. |
| Angelini Pharma S.p.A. | Bidding Company/Buyer | Company | A pharmaceutical company receiving exclusive rights to commercialize radiprodil outside North America. |
| Goodwin | Legal Advisor | Company | Provided legal advisory services for the collaboration agreement between GRIN Therapeutics and Angelini Pharma. |
| Blackstone Life Sciences | Other | Company | Blackstone Life Sciences is the parent company of Neurvati Neurosciences, with GRIN Therapeutics as its affiliate. |